

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Insulin is necessary but not sufficient: changing... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/9-827/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/9-827" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Insulin is necessary but not sufficient: changing the therapeutic paradigm in type 1 diabetes" />
    
            <meta name="og:title" content="F1000Research Article: Insulin is necessary but not sufficient: changing the therapeutic paradigm in type 1 diabetes.">
            <meta name="og:description" content="Read the latest article version by Sandra Lord, Carla J. Greenbaum, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="24032">
            <meta name="article-id" content="21801">
            <meta name="dc.title" content="Insulin is necessary but not sufficient: changing the therapeutic paradigm in type 1 diabetes">
            <meta name="dc.description" content="Despite the clear evidence that type 1 diabetes (T1D) begins well before hyperglycemia is evident, there are no clinically available disease-modifying therapies for early-stage disease. However, following the exciting results of the Teplizumab Prevention Study, the first study to demonstrate that overt T1D can be delayed with immunotherapy, there is renewed optimism that in the future, T1D will be treated before hyperglycemia develops. A different treatment paradigm is needed, as a majority of people with T1D do not meet the glycemic targets that are associated with a lower risk of T1D complications and therefore remain vulnerable to complications and shortened life expectancy. The following review will outline the history and current status of immunotherapy for T1D and highlight some challenges and ideas for the future. Although such efforts have been worldwide, we will focus particularly on the activities of Diabetes TrialNet, a National Institutes of Health consortium launched in 2004.">
            <meta name="dc.subject" content="Type 1 diabetes, immunotherapy, islet autoimmunity, prevention, teplizumab, TrialNet ">
            <meta name="dc.creator" content="Lord, Sandra">
            <meta name="dc.creator" content="Greenbaum, Carla J.">
            <meta name="dc.date" content="2020/07/30">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.21801.1">
            <meta name="dc.source" content="F1000Research 2020 9:827">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="Type 1 diabetes">
            <meta name="prism.keyword" content="immunotherapy">
            <meta name="prism.keyword" content="islet autoimmunity">
            <meta name="prism.keyword" content="prevention">
            <meta name="prism.keyword" content="teplizumab">
            <meta name="prism.keyword" content="TrialNet ">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2020/07/30">
            <meta name="prism.volume" content="9">
            <meta name="prism.number" content="827">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.21801.1">
            <meta name="prism.url" content="https://f1000research.com/articles/9-827">
            <meta name="citation_title" content="Insulin is necessary but not sufficient: changing the therapeutic paradigm in type 1 diabetes">
            <meta name="citation_abstract" content="Despite the clear evidence that type 1 diabetes (T1D) begins well before hyperglycemia is evident, there are no clinically available disease-modifying therapies for early-stage disease. However, following the exciting results of the Teplizumab Prevention Study, the first study to demonstrate that overt T1D can be delayed with immunotherapy, there is renewed optimism that in the future, T1D will be treated before hyperglycemia develops. A different treatment paradigm is needed, as a majority of people with T1D do not meet the glycemic targets that are associated with a lower risk of T1D complications and therefore remain vulnerable to complications and shortened life expectancy. The following review will outline the history and current status of immunotherapy for T1D and highlight some challenges and ideas for the future. Although such efforts have been worldwide, we will focus particularly on the activities of Diabetes TrialNet, a National Institutes of Health consortium launched in 2004.">
            <meta name="citation_description" content="Despite the clear evidence that type 1 diabetes (T1D) begins well before hyperglycemia is evident, there are no clinically available disease-modifying therapies for early-stage disease. However, following the exciting results of the Teplizumab Prevention Study, the first study to demonstrate that overt T1D can be delayed with immunotherapy, there is renewed optimism that in the future, T1D will be treated before hyperglycemia develops. A different treatment paradigm is needed, as a majority of people with T1D do not meet the glycemic targets that are associated with a lower risk of T1D complications and therefore remain vulnerable to complications and shortened life expectancy. The following review will outline the history and current status of immunotherapy for T1D and highlight some challenges and ideas for the future. Although such efforts have been worldwide, we will focus particularly on the activities of Diabetes TrialNet, a National Institutes of Health consortium launched in 2004.">
            <meta name="citation_keywords" content="Type 1 diabetes, immunotherapy, islet autoimmunity, prevention, teplizumab, TrialNet ">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Sandra Lord">
            <meta name="citation_author_institution" content="Benaroya Research Institute at Virginia Mason, Seattle, WA, 98101, USA">
            <meta name="citation_author" content="Carla J. Greenbaum">
            <meta name="citation_author_institution" content="Benaroya Research Institute at Virginia Mason, Seattle, WA, 98101, USA">
            <meta name="citation_publication_date" content="2020/07/30">
            <meta name="citation_volume" content="9">
            <meta name="citation_publication_number" content="827">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.21801.1">
            <meta name="citation_firstpage" content="827">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/9-827/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/9-827.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=24032 /> <input type=hidden id=articleId name=articleId value=21801 /> <input type=hidden id=xmlUrl value="/articles/9-827/v1/xml"/> <input type=hidden id=xmlFileName value="-9-827-v1.xml"> <input type=hidden id=article_uuid value=3e5482a1-c3d1-4f0e-ab14-b9277814a65c /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Insulin is necessary but not sufficient: changing the therapeutic paradigm in type 1 diabetes"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.21801.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.21801.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/9-827"
  },
  "headline": "Insulin is necessary but not sufficient: changing the therapeutic paradigm in type 1 diabetes",
  "datePublished": "2020-07-30T14:56:10",
  "dateModified": "2020-07-30T14:56:10",
  "author": [
    {
      "@type": "Person",
      "name": "Sandra Lord"
    },    {
      "@type": "Person",
      "name": "Carla J. Greenbaum"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Despite the clear evidence that type 1 diabetes (T1D) begins well before hyperglycemia is evident, there are no clinically available disease-modifying therapies for early-stage disease. However, following the exciting results of the Teplizumab Prevention Study, the first study to demonstrate that overt T1D can be delayed with immunotherapy, there is renewed optimism that in the future, T1D will be treated before hyperglycemia develops. A different treatment paradigm is needed, as a majority of people with T1D do not meet the glycemic targets that are associated with a lower risk of T1D complications and therefore remain vulnerable to complications and shortened life expectancy. The following review will outline the history and current status of immunotherapy for T1D and highlight some challenges and ideas for the future. Although such efforts have been worldwide, we will focus particularly on the activities of Diabetes TrialNet, a National Institutes of Health consortium launched in 2004."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/9-827/v1",
            "name": "Insulin is necessary but not sufficient: changing the therapeutic..."
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Insulin is necessary but not sufficient: changing the therapeutic... </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=24032 data-id=21801 data-downloads="" data-views="" data-scholar="10.12688/f1000research.21801.1" data-recommended="" data-doi="10.12688/f1000research.21801.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/9-827/v1/pdf?article_uuid=3e5482a1-c3d1-4f0e-ab14-b9277814a65c" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-21801-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-21801-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-21801-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Lord S and Greenbaum CJ. Insulin is necessary but not sufficient: changing the therapeutic paradigm in type 1 diabetes [version 1; peer review: 5 approved]</span>. <i>F1000Research</i> 2020, <b>9</b>(Faculty Rev):827 (<a class=new-orange href="https://doi.org/10.12688/f1000research.21801.1" target=_blank>https://doi.org/10.12688/f1000research.21801.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-21801-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=21801 id=track-article-signin-21801 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/21801?target=/articles/9-827/v1">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=24032 /> <input name=articleId type=hidden value=21801 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Insulin is necessary but not sufficient: changing the therapeutic paradigm in type 1 diabetes</h1><span class=other-info> [version 1; peer review: 5 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class=""><a href="mailto:slord@benaroyaresearch.org" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Sandra Lord</span></a><a href="https://orcid.org/0000-0003-4451-9800" target=_blank id=author-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0003-4451-9800</div>,&nbsp;</span><span class=""><a href="mailto:cjgreen@benaroyaresearch.org" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Carla J. Greenbaum</span></a></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class=""><a href="mailto:slord@benaroyaresearch.org" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Sandra Lord</span></a><a href="http://orcid.org/0000-0003-4451-9800" target=_blank id=mauthor-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0003-4451-9800</div>,&nbsp;</span><span class=""><a href="mailto:cjgreen@benaroyaresearch.org" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Carla J. Greenbaum</span></a></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 30 Jul 2020 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.21801.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Benaroya Research Institute at Virginia Mason, Seattle, WA, 98101, USA<br/> <p> <div class=margin-bottom> Sandra Lord <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation </div> <div class=margin-bottom> Carla J. Greenbaum <br/> <span>Roles: </span> Conceptualization, Supervision, Writing – Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=73268-68409></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=73272-68407></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=73271-68406></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=73269-68410></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=73270-68405></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Despite the clear evidence that type 1 diabetes (T1D) begins well before hyperglycemia is evident, there are no clinically available disease-modifying therapies for early-stage disease. However, following the exciting results of the Teplizumab Prevention Study, the first study to demonstrate that overt T1D can be delayed with immunotherapy, there is renewed optimism that in the future, T1D will be treated before hyperglycemia develops. A different treatment paradigm is needed, as a majority of people with T1D do not meet the glycemic targets that are associated with a lower risk of T1D complications and therefore remain vulnerable to complications and shortened life expectancy. The following review will outline the history and current status of immunotherapy for T1D and highlight some challenges and ideas for the future. Although such efforts have been worldwide, we will focus particularly on the activities of Diabetes TrialNet, a National Institutes of Health consortium launched in 2004. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> Type 1 diabetes, immunotherapy, islet autoimmunity, prevention, teplizumab, TrialNet </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Sandra Lord (<a href="mailto:slord@benaroyaresearch.org">slord@benaroyaresearch.org</a>) <br> Carla J. Greenbaum (<a href="mailto:cjgreen@benaroyaresearch.org">cjgreen@benaroyaresearch.org</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding authors:</b> Sandra Lord, Carla J. Greenbaum </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> The authors received research support from Janssen, Bristol-Meyers-Squibb and are participating in clinical trials sponsored by Intrexon and ProventionBio. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> This work was supported by National Institutes of Health grants U01DK106693, U01USF6163-1082-00-BY, and U01DK103282. <br/> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2020 Lord S and Greenbaum CJ. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Lord S and Greenbaum CJ. Insulin is necessary but not sufficient: changing the therapeutic paradigm in type 1 diabetes [version 1; peer review: 5 approved]</span>. <i>F1000Research</i> 2020, <b>9</b>(Faculty Rev):827 (<a href="https://doi.org/10.12688/f1000research.21801.1" target=_blank>https://doi.org/10.12688/f1000research.21801.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 30 Jul 2020, <b>9</b>(Faculty Rev):827 (<a href="https://doi.org/10.12688/f1000research.21801.1" target=_blank>https://doi.org/10.12688/f1000research.21801.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 30 Jul 2020, <b>9</b>(Faculty Rev):827 (<a href="https://doi.org/10.12688/f1000research.21801.1" target=_blank>https://doi.org/10.12688/f1000research.21801.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d41667e153>Introduction</h2><p class="" id=d41667e156>Nearly 100 years after its first clinical use, insulin remains the primary treatment of type 1 diabetes (T1D). Additionally, although T1D begins with asymptomatic but detectable islet autoimmunity, it is not treated until hyperglycemia begins. Certainly, there have been therapeutic improvements in T1D management, namely increasingly physiologic insulins and insulin delivery methods, continuous glucose monitoring, and closed-loop “artificial pancreas” systems. With these improvements, there have been corresponding reductions in short- and long-term complication rates. But only a minority of people living with T1D meet the hemoglobin A1c (a blood test that estimates the previous two- to three-month average glycemic control) targets that are associated with a lower risk of complications. This was suggested by 2014 data from the T1D Exchange (<a target=xrefwindow href="https://t1dexchange.org/" id=d41667e158>https://t1dexchange.org/</a>) in which only 17 to 23% of patients under 18 years old, 14% of those from 18 to 25 years old, and 30% of those over 25 years old had an A1c recommended by American Diabetes Association guidelines<sup><a href="#ref-1">1</a></sup>. Furthermore, T1D Exchange data from 2016 to 2018 indicate that these statistics have not improved despite the increasing use of devices<sup><a href="#ref-2">2</a></sup>. Even with adequate glycemic control, T1D management presents a financial, cognitive, and emotional strain for individuals and families. Clearly, there is an unmet need to treat T1D in earlier stages, when islet autoimmunity is apparent but before hyperglycemia begins, and it seems clear that immunotherapy will play a role. There are now five immunotherapies with demonstrated efficacy in preserving insulin secretion shortly after a T1D diagnosis. Additionally, with the results of the TrialNet Teplizumab Prevention Study<sup><a href="#ref-3">3</a></sup>, there is renewed optimism that clinical T1D can be delayed or prevented altogether.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d41667e177>Type 1 diabetes begins with islet autoimmunity</h2><p class="" id=d41667e180>T1D was first categorized as an autoimmune disease over 40 years ago with the identification of islet-specific antibodies in pancreatic islets and blood<sup><a href="#ref-4">4</a>,<a href="#ref-5">5</a></sup>. Since then, both longitudinal and cross-sectional studies have described the natural history of the disease, which requires both a genetic predisposition and environmental trigger(s) and then progresses along a predictable path toward islet autoimmunity. The highest genetic risk in people of European background is conferred by HLA class II DR3/4 genes, suggesting an important role of CD4<sup>+ </sup>T cells, although an increasing number of non-HLA risk genes have been identified<sup><a href="#ref-6">6</a></sup>. There are five well-validated autoantibodies associated with T1D: antibodies to glutamic acid decarboxylase, antibodies to insulin (insulin autoantibodies), antibodies to insulinoma-associated protein (IA-2), islet cell antibodies, and antibodies to a zinc transporter (ZnT8). Clinical T1D becomes inevitable with the development of two or more autoantibodies. This disease model described in a consensus conference<sup><a href="#ref-7">7</a></sup> is illustrated by Diabetes TrialNet (<a target=xrefwindow href="https://www.trialnet.org/" id=d41667e200>https://www.trialnet.org/</a>) in <a href="#f1">Figure 1</a>, where stage 1 T1D corresponds to two or more antibodies with normal glucose tolerance, stage 2 corresponds to two or more antibodies with abnormal glucose tolerance but still no persistent hyperglycemia, and stage 3 corresponds to a clinical diagnosis of T1D.</p><a name=f1 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/24032/d50540c2-1cb5-440c-a7a3-39145fc2da10_figure1.gif"><img alt="d50540c2-1cb5-440c-a7a3-39145fc2da10_figure1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/24032/d50540c2-1cb5-440c-a7a3-39145fc2da10_figure1.gif"></a><div class=caption><h3>Figure 1. The stages of type 1 diabetes (T1D).</h3><p id=d41667e218>Diabetes TrialNet was created in 2004 by the National Institutes of Health with the objective of conducting research studies to prevent T1D. It is an international network of T1D researchers who are exploring ways to prevent, delay, and slow the progression of the disease. Reprinted with permission from Diabetes TrialNet.</p></div></div><p class="" id=d41667e224>With the understanding that islet autoimmunity is early-stage T1D, there is greater urgency for identification of at-risk individuals. One approach is to screen for autoantibodies in those with increased genetic risk, as defined by a family history of T1D or by high-risk HLA testing at birth. But screening based on family history or genetic risk only is insufficient to identify all of those who will develop disease, as about 85% of people with T1D have no first-degree relative with T1D and only about 50% of Caucasians with diagnosed T1D have the highest-risk HLA class II DR3/4 haplotype. Another approach is to offer periodic autoantibody testing to everyone, perhaps in the pre-school years. This approach would identify most people destined to develop T1D by puberty: of this group, 64% will already have autoantibodies by age two and 95% will have autoantibodies by age five<sup><a href="#ref-8">8</a></sup>. General population screening was piloted in the Fr1da study<sup><a href="#ref-9">9</a></sup>, in which about 90,000 Bavarian children from ages two to five were screened for islet autoantibodies. As recently reported<sup><a href="#ref-9">9</a></sup>, Fr1da suggested that the risk of progression from early-stage T1D to clinical T1D is similar in the general population compared with individuals with a genetic risk of T1D. Like other studies, Fr1da found that the incidence of diabetic ketoacidosis (DKA) (3.2%) was lower at the time of clinical T1D diagnosis as compared with rates of DKA at diagnoses with usual care, which are reported to be 40 to 59%<sup><a href="#ref-10">10</a>,<a href="#ref-11">11</a></sup>. Overall, the Fr1da results support the feasibility and utility of population-wide autoantibody screening.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d41667e249>Immunotherapy works and is safe</h2><div class=section><a name=d41667e252 class=n-a></a><h3 class=section-title>New-onset studies</h3><p class="" id=d41667e257>Multiple immunotherapies have been tested in new-onset T1D (within 100 days of diagnosis) with a goal of preserving remaining endogenous insulin secretion, as measured by C-peptide. C-peptide is secreted with insulin in equimolar amounts and can be used as a marker of endogenous insulin secretion after insulin therapy is started. Five immunotherapies with an acceptable side effect/safety profile have been shown to preserve insulin secretion in newly diagnosed T1D: teplizumab and otelixizumab<sup><a href="#ref-12">12</a></sup>, rituximab, abatacept, low-dose anti-thymocyte globulin (ATG), and alefacept. These agents and studies are described in <a href="#T1">Table 1</a>. Notably, the beneficial effect of therapy on C-peptide is most apparent soon after randomization. The decline in C-peptide eventually parallels the control groups, indicating that therapy has not halted the disease. However, for several therapies, there remain significant differences between treatment arms in C-peptide level even years later. These differences may be clinically important, as multiple studies have shown the benefits of C-peptide preservation, including a lower risk of chronic complications and severe hypoglycemia even in subjects with a barely detectable C-peptide level<sup><a href="#ref-13">13</a>–<a href="#ref-15">15</a></sup>.</p><a name=T1 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 1. Five selected immunotherapies with proven efficacy to preserve C-peptide at 1 and/or 2 years post randomization in phase 2 studies in new-onset type 1 diabetes (within 100 days of diagnosis).</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d41667e285 class=n-a></a><thead><a name=d41667e287 class=n-a></a><tr><a name=d41667e289 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d41667e291 class=n-a></a>Agent tested</th><th align=left colspan=1 rowspan=1 valign=top><a name=d41667e294 class=n-a></a>Mechanism of action</th><th align=left colspan=1 rowspan=1 valign=top><a name=d41667e297 class=n-a></a>Drug administration</th><th align=left colspan=1 rowspan=1 valign=top><a name=d41667e300 class=n-a></a>Reference(s)</th></tr></thead><tbody><a name=d41667e305 class=n-a></a><tr><a name=d41667e307 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d41667e309 class=n-a></a>Abatacept</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41667e312 class=n-a></a>CTLA4 immunoglobulin (Ig), co-<br class=br>stimulatory blockade: disrupts antigen<br class=br>presentation</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41667e319 class=n-a></a>Monthly intravenous (iv) infusion for 2 years</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41667e322 class=n-a></a><a href="#ref-25">25</a>,<a href="#ref-26">26</a></td></tr><tr><a name=d41667e330 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d41667e332 class=n-a></a>Alefacept</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41667e335 class=n-a></a>LFA-3 Ig: inhibition of activated T cells<br class=br>(primarily memory T cells)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41667e340 class=n-a></a>Two courses of 12 weekly intramuscular (im)<br class=br>injections, separated by a 12-week pause</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41667e345 class=n-a></a><a href="#ref-27">27</a>,<a href="#ref-28">28</a></td></tr><tr><a name=d41667e353 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d41667e355 class=n-a></a>Low-dose (2.5 mg/kg) anti-<br class=br>thymocyte globulin (ATG)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41667e360 class=n-a></a>Lymphocyte depletion</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41667e363 class=n-a></a>One course of two iv infusions over 2 to 3 days</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41667e366 class=n-a></a><a href="#ref-29">29</a>,<a href="#ref-30">30</a></td></tr><tr><a name=d41667e374 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d41667e376 class=n-a></a>Rituximab</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41667e379 class=n-a></a>Anti-CD20, anti-B cell: disrupts antigen<br class=br>presentation</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41667e384 class=n-a></a>One course of four weekly iv infusions</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41667e387 class=n-a></a><a href="#ref-31">31</a>,<a href="#ref-32">32</a></td></tr><tr><a name=d41667e395 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d41667e397 class=n-a></a>Teplizumab (multiple<br class=br>studies)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41667e402 class=n-a></a>Anti-CD3, inhibition of activated T cells</td><td align=left colspan=1 rowspan=1 valign=top><a name=d41667e405 class=n-a></a>One course of 14 daily iv infusions. Immune<br class=br>Tolerance Network new-onset teplizumab study<br class=br>(AbATE) gave a second 14-day infusion 1 year later. </td><td align=left colspan=1 rowspan=1 valign=top><a name=d41667e412 class=n-a></a><a href="#ref-33">33</a>,<a href="#ref-34">34</a>,<a href="#ref-35">35</a></td></tr></tbody></table></div></div><div class=section><a name=d41667e426 class=n-a></a><h3 class=section-title>Prevention of clinical disease</h3><p class="" id=d41667e431>Although multiple agents have proven efficacious in new-onset T1D, disease prevention has been more elusive. In 2011, TrialNet launched the Teplizumab Prevention Study in a cohort of high-risk individuals with multiple autoantibodies and impaired glucose tolerance but without clinical T1D. Teplizumab is an anti-CD3 monoclonal antibody that does not bind the Fc receptor but does disrupt autoreactive T-cell function and may enhance regulatory T-cell function. The results of the TrialNet study, published online in the <i>New England Journal of Medicine</i> in June 2019<sup><a href="#ref-3">3</a></sup>, provide the first evidence that clinical T1D can be delayed with immunotherapy. Seventy-six participants received 14 daily infusions of placebo or teplizumab, followed by regular monitoring with oral glucose tolerance testing. At study end, participants who received teplizumab had a median 24-month delay in clinical T1D diagnosis as compared with participants who received placebo (<a href="#f2">Figure 2</a>). Importantly, there was no difference in new infections between placebo- and teplizumab-treated cohorts, confirming safety outcomes from the new-onset teplizumab studies. Ongoing monitoring of participants who had not yet developed T1D at study end will provide additional information about safety, potential duration of benefit, and characteristics of long-term responders.<b></b></p><a name=f2 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/24032/d50540c2-1cb5-440c-a7a3-39145fc2da10_figure2.gif"><img alt="d50540c2-1cb5-440c-a7a3-39145fc2da10_figure2.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/24032/d50540c2-1cb5-440c-a7a3-39145fc2da10_figure2.gif"></a><div class=caption><h3>Figure 2. The median times to diagnosis to clinical type 1 diabetes (T1D) were 48.4 months in the teplizumab group and 24.4 months in the placebo group.</h3><p id=d41667e455>This figure was reproduced from Herold <i>et al</i>.<sup><a href="#ref-3">3</a></sup>. Copyright © (2019) Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.</p></div></div><p class="" id=d41667e469>The Teplizumab Prevention Study provides a framework for testing additional immunotherapies with proven efficacy in new-onset T1D prior to clinical disease. TrialNet is testing the CTLA 4-Fc fusion protein abatacept in individuals with multiple autoantibodies to see whether it can delay clinical T1D<sup><a href="#ref-16">16</a></sup> and will soon launch a study of the anti–B cell agent rituximab followed by abatacept, also in an at-risk population<sup><a href="#ref-17">17</a></sup>. This combination study is described below (in the ‘Combination or sequential use of therapies may provide therapeutic synergy’ section). Another TrialNet study under consideration will investigate whether clinical T1D can be delayed in a high-risk population with multiple autoantibodies using low-dose ATG.</p><p class="" id=d41667e480>Whereas teplizumab, abatacept, rituximab, and ATG have been or are being considered for T1D prevention following their positive outcomes in recently diagnosed individuals, other therapies can be tested for T1D prevention or progression without being tested first in new-onset T1D. For example, previous trials have tested parenteral, nasal, and oral insulin<sup><a href="#ref-18">18</a>–<a href="#ref-21">21</a></sup>; nicotinamide<sup><a href="#ref-22">22</a></sup>; and hydrolysed casein cow’s milk formula<sup><a href="#ref-23">23</a>,<a href="#ref-24">24</a></sup>. Although the primary outcomes of these agents were negative, these therapies are known to be safe and have scientific rationale for use in early-stage T1D. The Global Platform for the Prevention of Autoimmune Diabetes is a multicenter European initiative to provide a framework for T1D primary prevention trials such as POInT (Primary Oral Insulin Trial)<sup><a href="#ref-22">22</a>,<a href="#ref-36">36</a></sup>. POInT will test whether oral insulin can delay or prevent the development of autoantibodies and T1D in genetically high-risk infants. Another ongoing prevention study is the TrialNet Hydroxychloroquine Prevention study, which is investigating whether hydroxychloroquine can delay or prevent progression to impaired glucose tolerance or clinical T1D (or both) in subjects with multiple autoantibodies and normal glucose tolerance. Hydroxychloroquine is a well-tolerated and inexpensive agent used historically for the treatment of malaria and currently for the treatment of rheumatoid arthritis and lupus. Although it has not been used in T1D, it has several immune properties anticipated to have beneficial effects in pre-clinical T1D, namely decreased cell activation, antigen presentation, and autoantibody production<sup><a href="#ref-37">37</a></sup>. An additional TrialNet prevention trial under development will test methyldopa, which is an alpha-adrenergic blocker used clinically for pregnancy-induced hypertension. Interestingly, it has a crystal structure that fits in the cleft of the major histocompatibility complex (MHC) class II molecule HLA-DQ8 that binds insulin peptides. Insulin is an early immune target in T1D; moreover, insulin autoantibody positivity has been associated with HLA DQ8 positivity<sup><a href="#ref-38">38</a>,<a href="#ref-39">39</a></sup>. In a small study of HLA-DQ8<sup>+</sup> patients with recent-onset T1D, methyldopa was shown to specifically block insulin peptide binding to HLA-DQ8 and to decrease inflammatory T-cell responses to insulin<sup><a href="#ref-40">40</a></sup>. TrialNet aims to launch a similar study testing the effects of methyldopa on antigen presentation in a DQ8<sup>+</sup> at-risk population of children and adults with insulin antibodies<sup><a href="#ref-41">41</a></sup>.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d41667e538>How to personalize immunotherapy in type 1 diabetes</h2><p class="" id=d41667e541>As demonstrated in new-onset studies, immunotherapy can preserve insulin secretion after diagnosis in some patients, but a significant portion of drug-treated patients have a C-peptide decline similar to that of placebo-treated patients. This was seen in the Immune Tolerance Network new-onset teplizumab study (AbATE), in which 45% of teplizumab-treated subjects maintained their C-peptide level at two years but 55% of teplizumab-treated individuals appeared indistinguishable from placebo-treated controls<sup><a href="#ref-42">42</a></sup>. Further work is needed to predict and monitor response to therapy and to decide when and whom to treat. The following section describes some early observations.</p><div class=section><a name=d41667e548 class=n-a></a><h3 class=section-title>Children respond well to therapy</h3><p class="" id=d41667e553>Although we no longer call T1D “juvenile” diabetes, many people with T1D are diagnosed as children and will live with T1D for decades. Several studies in new-onset T1D suggest that it may be easier to demonstrate the benefits of immunotherapy in children as compared with adults. For example, the positive result seen in both the rituximab and abatacept new-onset studies primarily reflected the response seen in children<sup><a href="#ref-31">31</a>,<a href="#ref-32">32</a>,<a href="#ref-43">43</a></sup>. Since these studies were not designed to compare effects between adults and children, this does not imply that therapy does not work in adults. Indeed, age was not identified as a factor of response in the Teplizumab Prevention Study. However, it is known that children lose insulin more rapidly and completely after diagnosis as compared with adults<sup><a href="#ref-44">44</a></sup>, suggesting more aggressive immune activity in children. In fact, 35% of individuals with T1D diagnosed after age 18 have detectable C-peptide 10 to 19 years after diagnosis as compared with only 9% of people whose T1D is diagnosed before age 18<sup><a href="#ref-45">45</a></sup>. Further evidence comes from insulitic profiles of pathology specimens<sup><a href="#ref-46">46</a></sup> and from RNA sequence data<sup><a href="#ref-47">47</a></sup> which support the concept that age affects immune phenotype in T1D. Taken together, these observations suggest that although both children and adults benefit from early intervention, the benefits to children may be more apparent. Moreover, in children, several years’ delay in clinical diagnosis is clinically important as adults tend to manage the demands of T1D better than teens and children do. Furthermore, because the incidence of T1D may decrease with age, a “pause” in immune activity might allow tolerance to develop naturally.</p></div><div class=section><a name=d41667e583 class=n-a></a><h3 class=section-title>Genetic characteristics</h3><p class="" id=d41667e588>HLA genes are the largest contributors to T1D risk; however, other genes encode proteins with direct or indirect immune effects on T1D pathophysiology. Interestingly, HLA genes appear to contribute primarily to the risk of autoantibody development with little contribution to progression once multiple antibodies are present<sup><a href="#ref-48">48</a>–<a href="#ref-50">50</a></sup>. Although the data evaluating the role of non-HLA genes are much less robust, some evidence suggests that non-HLA genes may contribute to progression from antibody positivity to overt T1D<sup><a href="#ref-51">51</a></sup>. There are also hints that HLA genes may affect response to therapy. For example, in the TrialNet Teplizumab Prevention Study, teplizumab-treated participants who were HLA-DR3<sup>−</sup>/DR4<sup>+</sup> had a delay in T1D diagnosis whereas DR3<sup>+</sup>/DR4<sup>−</sup> individuals progressed similarly to individuals who received placebo.</p></div><div class=section><a name=d41667e616 class=n-a></a><h3 class=section-title>Immune characteristics</h3><p class="" id=d41667e621>Whereas baseline immune characteristics have not yet been associated with response to therapy, post-treatment immune phenotypes are more commonly identified in responders as compared with non-responders. This was seen in both AbATE and the TrialNet Teplizumab Prevention Study, where individuals with markers of T-cell exhaustion (associated with prolonged antigen stimulation and loss of CD8 effector function) were shown to have responded better to teplizumab treatment<sup><a href="#ref-3">3</a>,<a href="#ref-33">33</a></sup>. Additionally, there are clues that immunotherapy may be most effective during periods of robust immune activity, as suggested by the Teplizumab Prevention Study, in which participants who began the study with a below-median C-peptide level (perhaps a marker of more active disease) responded better to teplizumab treatment as compared with those who started treatment with a C-peptide level above the median<sup><a href="#ref-3">3</a></sup>. Such markers might be used to identify therapeutic windows for treatment both initially and during a relapse.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d41667e639>Looking to the future</h2><p class="" id=d41667e642>Despite significant improvements over the last 100 years, most individuals with T1D do not meet therapeutic targets and remain vulnerable to complications, suggesting that current insulin delivery technologies are not enough. The T1D disease model has changed: islet autoimmunity, as measured by two or more T1D-specific autoantibodies, is now considered the first stage of T1D. Early treatment with immunotherapy to prevent tissue destruction and loss of function is already the standard of care in other autoimmune conditions, such as rheumatoid arthritis or multiple sclerosis. It is likely that immune therapy prior to and/or shortly after clinical diagnosis will be part of routine care in T1D. Moreover, though not addressed in this review, approaches to directly target beta cells may also become part of T1D therapy.</p><div class=section><a name=d41667e645 class=n-a></a><h3 class=section-title>Consider alternative study designs to speed study enrolment and completion while decreasing cost</h3><p class="" id=d41667e650>Analysis of surrogate endpoints earlier in the development of T1D might decrease the time needed to evaluate treatment efficacy. Given the inevitability of clinical T1D once there are two or more autoantibodies, the development of islet autoimmunity might be used as an intermediate endpoint for primary prevention studies. Similarly, because islet autoimmunity with normal glucose tolerance progresses to islet autoimmunity with abnormal glucose tolerance and then to clinical T1D, the development of abnormal glucose tolerance is being used as a study endpoint in studies testing therapy to delay progression from islet autoimmunity to T1D. This approach is being tested in the TrialNet Abatacept in Prevention and Hydroxychloroquine in Prevention studies, described earlier<sup><a href="#ref-16">16</a>,<a href="#ref-37">37</a></sup>. Adaptive trial designs<sup><a href="#ref-52">52</a></sup>, studies with mechanistic or composite endpoints<sup><a href="#ref-53">53</a></sup>, or single-arm studies might be conducted as alternatives to the “gold standard” placebo-controlled trial, both to facilitate participant recruitment and to reduce cost. With considerable amounts of T1D natural history data available, it is feasible that existing data sets may be used in a single-arm study to obviate the need for a placebo cohort.</p></div><div class=section><a name=d41667e669 class=n-a></a><h3 class=section-title>General population screening will be needed to identify most people with islet autoimmunity</h3><p class="" id=d41667e674>As outlined earlier, this might be accomplished with genetic testing at birth followed by periodic autoantibody testing in those who have high-risk genes or a family history of T1D or with periodic autoantibody testing for everyone. However it is accomplished, general population screening is costly and will require considerable effort in education and counselling for those who are identified as being at risk and have no experience with T1D. Screening family members for T1D risk can be anxiety-provoking, as learning that oneself or one’s child is at high risk creates stress and uncertainty and may create discrimination or alter life plans. Despite this, studies suggest that the initial anxiety associated with screening dissipates with repeated testing<sup><a href="#ref-54">54</a></sup>. Further work found that when T1D is diagnosed through screening efforts, there is less stress than in families diagnosed without risk screening<sup><a href="#ref-55">55</a></sup>. The Fr1da study suggests a similar pattern in those without T1D in their families: parental stress was higher after receiving a diagnosis of early-stage T1D as compared with those who received negative test results but this declined in the year after testing<sup><a href="#ref-9">9</a></sup>. Moreover, as reported in Fr1da, parental stress was lower in the cohort whose children were diagnosed with early-stage asymptomatic T1D compared with a cohort from the DiMelli study<sup><a href="#ref-56">56</a></sup> whose children were diagnosed with clinical T1D without prior staging.</p></div><div class=section><a name=d41667e694 class=n-a></a><h3 class=section-title>Chronic immunotherapy may be necessary</h3><p class="" id=d41667e699>Despite early optimism that a short course of immunotherapy would produce a durable or permanent remission through restoration of self-tolerance, this has not been the case, nor has it been true in any other autoimmune disease. It is likely that chronic or intermittent treatment will be needed to preserve beta-cell function and prevent progression of disease<sup><a href="#ref-57">57</a></sup>. This strategy has not been tested in T1D but becomes increasingly feasible as new and safer immunotherapies become available for the long-term therapy of other autoimmune diseases.</p></div><div class=section><a name=d41667e708 class=n-a></a><h3 class=section-title>Combination or sequential use of therapies may provide therapeutic synergy</h3><p class="" id=d41667e713>There is a precedent for combination immunotherapies in other immune-mediated diseases, such as the combination of methotrexate and etanercept in rheumatoid arthritis<sup><a href="#ref-58">58</a></sup> or azathioprine plus infliximab in Crohn’s disease<sup><a href="#ref-59">59</a></sup>. TrialNet aims to launch a study in a high-risk population with multiple autoantibodies and impaired glucose tolerance that will evaluate the effect on disease progression with rituximab followed by abatacept. The combination treatment was suggested by findings from each of the abatacept and rituximab monotherapy new-onset trials. In the abatacept study, participants with a high B-cell signature six months after the start of therapy were less likely to have responded to abatacept treatment<sup><a href="#ref-60">60</a></sup>. Similarly, in the rituximab study, participants with a high activated T-cell signature six months after rituximab treatment were less likely to have responded to rituximab therapy<sup><a href="#ref-61">61</a></sup>. In the planned TrialNet combination study, four weekly treatments with rituximab will deplete CD20<sup>+</sup> B cells. Then four months later, prior to B-cell recovery, abatacept treatment will start and continue for two years. Abatacept is expected to interfere with T-cell help necessary to B-cell recovery, thus precluding recovery of autoreactive B cells.</p></div><div class=section><a name=d41667e736 class=n-a></a><h3 class=section-title>Lower cost and greater convenience of immunotherapy are anticipated</h3><p class="" id=d41667e741>Although immunotherapy is expensive and inconvenient, so is a lifetime of T1D. A 2019 report by the Health Care Cost Institute (<a target=xrefwindow href="https://www.healthcostinstitute.org/research/publications/entry/spending-on-individuals-with-type-1-diabetes-and-the-role-of-rapidly-increasing-insulin-prices" id=d41667e743>https://www.healthcostinstitute.org/research/publications/entry/spending-on-individuals-with-type-1-diabetes-and-the-role-of-rapidly-increasing-insulin-prices</a>) estimates that the 2016 average annual health-care spending for a person with T1D was $18,494 and this does not include indirect costs. Although the specific costs of each approach are currently unknown, it is expected that oral and subcutaneous versions of immunotherapies that can be administered at home will increase the feasibility of immunotherapy for T1D and that the increasing availability of “bioequivalent” or generic versions will decrease cost. Thus, we are reaching a point where even long-term preventative immunotherapy may be more cost-effective than lifelong T1D treatment.</p></div><div class=section><a name=d41667e748 class=n-a></a><h3 class=section-title>Greater advocacy is needed</h3><p class="" id=d41667e753>To shift the T1D treatment paradigm, a multifaceted approach will be needed: to understand the ongoing burden of T1D despite therapeutic successes; to normalize the new T1D disease model, that is, that T1D begins long before hyperglycemia; and to recognize the potential for immunotherapy to modify the underlying disease. People not affected by T1D (including clinicians) may be under the impression that T1D can be managed with minimal effort and minimal risk. This impression ignores the evidence that a majority of people living with T1D do not meet recommended therapeutic targets. As a result, people with T1D (and type 2 diabetes) may apologize for their disease management rather sharing their daily struggles with the disease, including the cost and mental/emotional burdens. In addition to the unmet need for relief from hyperglycemia, greater awareness that islet autoimmunity is a precursor to clinical T1D is needed. With this understanding, it seems natural to shift the therapeutic paradigm from treating hyperglycemia to preventing hyperglycemia. Although immunotherapy is not yet ready for clinical use in T1D, with the results of the Teplizumab Prevention Study—the first study to show that clinical T1D diagnosis can be delayed with immunotherapy—the possibility seems closer than ever.</p></div></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d41667e761 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class=faculty-opinion-icon></span><span class="prime-red big">Faculty Opinions recommended</span></span><h2 class=main-title id=d42092>References</h2><div class="section ref-list"><a name=d41667e761 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d41667e768 class=n-a></a>Miller KM, Foster NC, Beck RW, <i> et al.</i>: Current state of type 1 diabetes treatment in the U.S.: Updated data from the T1D Exchange clinic registry. <i>Diabetes Care.</i> 2015; <b>38</b>(6): 971–8. <a target=xrefwindow id=d41667e779 href="http://www.ncbi.nlm.nih.gov/pubmed/25998289">PubMed Abstract </a> | <a target=xrefwindow id=d41667e782 href="https://doi.org/10.2337/dc15-0078">Publisher Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/734882711"><span class="faculty-opinion-icon small"></span></a><a name=d41667e791 class=n-a></a>Foster NC, Beck RW, Miller KM, <i> et al.</i>: State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016-2018. <i>Diabetes Technol Ther.</i> 2019; <b>21</b>(2): 66–72. <a target=xrefwindow id=d41667e802 href="http://www.ncbi.nlm.nih.gov/pubmed/30657336">PubMed Abstract </a> | <a target=xrefwindow id=d41667e805 href="https://doi.org/10.1089/dia.2018.0384">Publisher Full Text </a> | <a target=xrefwindow id=d41667e809 href="http://www.ncbi.nlm.nih.gov/pmc/articles/7061293">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/734882711">Faculty Opinions Recommendation</a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/735949131"><span class="faculty-opinion-icon small"></span></a><a name=d41667e822 class=n-a></a>Herold KC, Bundy BN, Long SA, <i> et al.</i>: An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. <i>N Engl J Med.</i> 2019; <b>381</b>(7): 603–13. <a target=xrefwindow id=d41667e833 href="http://www.ncbi.nlm.nih.gov/pubmed/31180194">PubMed Abstract </a> | <a target=xrefwindow id=d41667e836 href="https://doi.org/10.1056/NEJMoa1902226">Publisher Full Text </a> | <a target=xrefwindow id=d41667e840 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6776880">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/735949131">Faculty Opinions Recommendation</a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d41667e853 class=n-a></a>Bottazzo G, Florin-Christensen A, Doniach D: Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. <i>Lancet.</i> 1974; <b>2</b>(7892): 1279–83. <a target=xrefwindow id=d41667e861 href="http://www.ncbi.nlm.nih.gov/pubmed/4139522">PubMed Abstract </a> | <a target=xrefwindow id=d41667e864 href="https://doi.org/10.1016/s0140-6736(74)90140-8">Publisher Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d41667e873 class=n-a></a>Gepts W: Pathologic anatomy of the pancreas in juvenile diabetes mellitus. <i>Diabetes.</i> 1965; <b>14</b>(10): 619–33. <a target=xrefwindow id=d41667e881 href="http://www.ncbi.nlm.nih.gov/pubmed/5318831">PubMed Abstract </a> | <a target=xrefwindow id=d41667e884 href="https://doi.org/10.2337/diab.14.10.619">Publisher Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d41667e894 class=n-a></a>Noble JA, Valdes AM, Cook M, <i> et al.</i>: The role of HLA class II genes in insulin-dependent diabetes mellitus: Molecular analysis of 180 Caucasian, multiplex families. <i>Am J Hum Genet.</i> 1996; <b>59</b>(5): 1134–48. <a target=xrefwindow id=d41667e905 href="http://www.ncbi.nlm.nih.gov/pubmed/8900244">PubMed Abstract </a> | <a target=xrefwindow id=d41667e908 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1914851">Free Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d41667e917 class=n-a></a>Insel RA, Dunne JL, Atkinson MA, <i> et al.</i>: Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association. <i>Diabetes Care.</i> 2015; <b>38</b>(10): 1964–74. <a target=xrefwindow id=d41667e928 href="http://www.ncbi.nlm.nih.gov/pubmed/26404926">PubMed Abstract </a> | <a target=xrefwindow id=d41667e931 href="https://doi.org/10.2337/dc15-1419">Publisher Full Text </a> | <a target=xrefwindow id=d41667e935 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5321245">Free Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d41667e944 class=n-a></a>Parikka V, Näntö-Salonen K, Saarinen M, <i> et al.</i>: Early seroconversion and rapidly increasing autoantibody concentrations predict prepubertal manifestation of type 1 diabetes in children at genetic risk. <i>Diabetologia.</i> 2012; <b>55</b>(7): 1926–36. <a target=xrefwindow id=d41667e955 href="http://www.ncbi.nlm.nih.gov/pubmed/22441569">PubMed Abstract </a> | <a target=xrefwindow id=d41667e958 href="https://doi.org/10.1007/s00125-012-2523-3">Publisher Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/737281149"><span class="faculty-opinion-icon small"></span></a><a name=d41667e967 class=n-a></a>Ziegler AG, Kick K, Bonifacio E, <i> et al.</i>: Yield of a Public Health Screening of Children for Islet Autoantibodies in Bavaria, Germany. <i>JAMA.</i> 2020; <b>323</b>(4): 339–51. <a target=xrefwindow id=d41667e978 href="http://www.ncbi.nlm.nih.gov/pubmed/31990315">PubMed Abstract </a> | <a target=xrefwindow id=d41667e981 href="https://doi.org/10.1001/jama.2019.21565">Publisher Full Text </a> | <a target=xrefwindow id=d41667e985 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6990943">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/737281149">Faculty Opinions Recommendation</a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/736742100"><span class="faculty-opinion-icon small"></span></a><a name=d41667e998 class=n-a></a>Alonso GT, Coakley A, Pyle L, <i> et al.</i>: Diabetic Ketoacidosis at Diagnosis of Type 1 Diabetes in Colorado Children, 2010-2017. <i>Diabetes Care.</i> 2020; <b>43</b>(1): 117–21. <a target=xrefwindow id=d41667e1009 href="http://www.ncbi.nlm.nih.gov/pubmed/31601639">PubMed Abstract </a> | <a target=xrefwindow id=d41667e1012 href="https://doi.org/10.2337/dc19-0428">Publisher Full Text </a> | <a target=xrefwindow id=d41667e1016 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6925579">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/736742100">Faculty Opinions Recommendation</a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d41667e1029 class=n-a></a>Rewers A, Dong F, Slover RH, <i> et al.</i>: Incidence of diabetic ketoacidosis at diagnosis of type 1 diabetes in Colorado youth, 1998-2012. <i>JAMA.</i> 2015; <b>313</b>(15): 1570–2. <a target=xrefwindow id=d41667e1040 href="http://www.ncbi.nlm.nih.gov/pubmed/25898057">PubMed Abstract </a> | <a target=xrefwindow id=d41667e1043 href="https://doi.org/10.1001/jama.2015.1414">Publisher Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/1026628"><span class="faculty-opinion-icon small"></span></a><a name=d41667e1053 class=n-a></a>Keymeulen B, Vandemeulebroucke E, Ziegler AG, <i> et al.</i>: Insulin Needs after CD3-Antibody Therapy in New-Onset Type 1 Diabetes. <i>N Engl J Med.</i> 2005; <b>352</b>(25): 2598–608. <a target=xrefwindow id=d41667e1064 href="http://www.ncbi.nlm.nih.gov/pubmed/15972866">PubMed Abstract </a> | <a target=xrefwindow id=d41667e1067 href="https://doi.org/10.1056/NEJMoa043980">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/1026628">Faculty Opinions Recommendation</a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d41667e1080 class=n-a></a>Steffes MW, Sibley S, Jackson M, <i> et al.</i>: Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. <i>Diabetes Care.</i> 2003; <b>26</b>(3): 832–6. <a target=xrefwindow id=d41667e1091 href="http://www.ncbi.nlm.nih.gov/pubmed/12610045">PubMed Abstract </a> | <a target=xrefwindow id=d41667e1094 href="https://doi.org/10.2337/diacare.26.3.832">Publisher Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/5311956"><span class="faculty-opinion-icon small"></span></a><a name=d41667e1103 class=n-a></a>Keenan HA, Sun JK, Levine J, <i> et al.</i>: Residual insulin production and pancreatic ß-cell turnover after 50 years of diabetes: Joslin Medalist Study. <i>Diabetes.</i> 2010; <b>59</b>(11): 2846–53. <a target=xrefwindow id=d41667e1114 href="http://www.ncbi.nlm.nih.gov/pubmed/20699420">PubMed Abstract </a> | <a target=xrefwindow id=d41667e1117 href="https://doi.org/10.2337/db10-0676">Publisher Full Text </a> | <a target=xrefwindow id=d41667e1121 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2963543">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/5311956">Faculty Opinions Recommendation</a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d41667e1134 class=n-a></a>Lachin JM, McGee P, Palmer JP: Impact of C-Peptide Preservation on Metabolic and Clinical Outcomes in the Diabetes Control and Complications Trial. <i>Diabetes.</i> 2014; <b>63</b>(2): 739–48. <a target=xrefwindow id=d41667e1142 href="http://www.ncbi.nlm.nih.gov/pubmed/24089509">PubMed Abstract </a> | <a target=xrefwindow id=d41667e1145 href="https://doi.org/10.2337/db13-0881">Publisher Full Text </a> | <a target=xrefwindow id=d41667e1148 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3900540">Free Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d41667e1157 class=n-a></a>National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK)CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At Risk for Type 1. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). [accessed 2019 July 15]. 2000. <a target=xrefwindow id=d41667e1159 href="https://www.clinicaltrials.gov/ct2/show/NCT01773707">Reference Source</a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d41667e1168 class=n-a></a>National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK), Rituximab and Abatacept for Prevention or Reversal of Type 1 Diabetes (TN25). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). (accessed 2019 July 15) 2000. <a target=xrefwindow id=d41667e1170 href="https://clinicaltrials.gov/ct2/show/NCT03929601">Reference Source</a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d41667e1180 class=n-a></a>Diabetes Prevention Trial--Type 1 Diabetes Study Group: Effects of Insulin in Relatives of Patients with Type 1 Diabetes Mellitus. <i>N Engl J Med.</i> 2002; <b>346</b>(22): 1685–91. <a target=xrefwindow id=d41667e1188 href="http://www.ncbi.nlm.nih.gov/pubmed/12037147">PubMed Abstract </a> | <a target=xrefwindow id=d41667e1191 href="https://doi.org/10.1056/NEJMoa012350">Publisher Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/717955695"><span class="faculty-opinion-icon small"></span></a><a name=d41667e1200 class=n-a></a>Näntö-Salonen K, Kupila A, Simell S, <i> et al.</i>: Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: A double-blind, randomised controlled trial. <i>Lancet.</i> 2008; <b>372</b>(9651): 1746–55. <a target=xrefwindow id=d41667e1211 href="http://www.ncbi.nlm.nih.gov/pubmed/18814906">PubMed Abstract </a> | <a target=xrefwindow id=d41667e1214 href="https://doi.org/10.1016/S0140-6736(08)61309-4">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/717955695">Faculty Opinions Recommendation</a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d41667e1227 class=n-a></a>Harrison LC, Honeyman MC, Steele CE, <i> et al.</i>: Pancreatic beta-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for type 1 diabetes. <i>Diabetes Care.</i> 2004; <b>27</b>(10): 2348–55. <a target=xrefwindow id=d41667e1238 href="http://www.ncbi.nlm.nih.gov/pubmed/15451899">PubMed Abstract </a> | <a target=xrefwindow id=d41667e1241 href="https://doi.org/10.2337/diacare.27.10.2348">Publisher Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d41667e1250 class=n-a></a>Krischer JP, Schatz DA, Bundy B, <i> et al.</i>: Effect of Oral Insulin on Prevention of Diabetes in Relatives of Patients With Type 1 Diabetes: A Randomized Clinical Trial. <i>JAMA.</i> 2017; <b>318</b>(19): 1891–1902. <a target=xrefwindow id=d41667e1261 href="http://www.ncbi.nlm.nih.gov/pubmed/29164254">PubMed Abstract </a> | <a target=xrefwindow id=d41667e1264 href="https://doi.org/10.1001/jama.2017.17070">Publisher Full Text </a> | <a target=xrefwindow id=d41667e1268 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5798455">Free Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d41667e1277 class=n-a></a>Lampeter EF, Klinghammer A, Scherbaum WA, <i> et al.</i>: The Deutsche Nicotinamide Intervention Study: An attempt to prevent type 1 diabetes. DENIS Group. <i>Diabetes.</i> 1998; <b>47</b>(6): 980–4. <a target=xrefwindow id=d41667e1288 href="http://www.ncbi.nlm.nih.gov/pubmed/9604880">PubMed Abstract </a> | <a target=xrefwindow id=d41667e1291 href="https://doi.org/10.2337/diabetes.47.6.980">Publisher Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/718443949"><span class="faculty-opinion-icon small"></span></a><a name=d41667e1300 class=n-a></a>Knip M, Åkerblom HK, Becker D, <i> et al.</i>: Hydrolyzed infant formula and early β-cell autoimmunity: A randomized clinical trial. <i>JAMA.</i> 2014; <b>311</b>(22): 2279–87. <a target=xrefwindow id=d41667e1311 href="http://www.ncbi.nlm.nih.gov/pubmed/24915259">PubMed Abstract </a> | <a target=xrefwindow id=d41667e1314 href="https://doi.org/10.1001/jama.2014.5610">Publisher Full Text </a> | <a target=xrefwindow id=d41667e1318 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4225544">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/718443949">Faculty Opinions Recommendation</a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/732395181"><span class="faculty-opinion-icon small"></span></a><a name=d41667e1332 class=n-a></a>Writing Group for the TRIGR Study Group, Knip M, Åkerblom HK, <i> et al.</i>: Effect of Hydrolyzed Infant Formula vs Conventional Formula on Risk of Type 1 Diabetes: The TRIGR Randomized Clinical Trial. <i>JAMA.</i> 2018; <b>319</b>(1): 38–48. <a target=xrefwindow id=d41667e1343 href="http://www.ncbi.nlm.nih.gov/pubmed/29297078">PubMed Abstract </a> | <a target=xrefwindow id=d41667e1346 href="https://doi.org/10.1001/jama.2017.19826">Publisher Full Text </a> | <a target=xrefwindow id=d41667e1350 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5833549">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/732395181">Faculty Opinions Recommendation</a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/717955698"><span class="faculty-opinion-icon small"></span></a><a name=d41667e1363 class=n-a></a>Orban T, Bundy B, Becker DJ, <i> et al.</i>: Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: A randomised, double-blind, placebo-controlled trial. <i>Lancet.</i> 2011; <b>378</b>(9789): 412–9. <a target=xrefwindow id=d41667e1374 href="http://www.ncbi.nlm.nih.gov/pubmed/21719096">PubMed Abstract </a> | <a target=xrefwindow id=d41667e1377 href="https://doi.org/10.1016/S0140-6736(11)60886-6">Publisher Full Text </a> | <a target=xrefwindow id=d41667e1381 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3462593">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/717955698">Faculty Opinions Recommendation</a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d41667e1394 class=n-a></a>Orban T, Bundy B, Becker DJ, <i> et al.</i>: Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: Follow-up 1 year after cessation of treatment. <i>Diabetes Care.</i> 2014; <b>37</b>(4): 1069–75. <a target=xrefwindow id=d41667e1405 href="http://www.ncbi.nlm.nih.gov/pubmed/24296850">PubMed Abstract </a> | <a target=xrefwindow id=d41667e1408 href="https://doi.org/10.2337/dc13-0604">Publisher Full Text </a> | <a target=xrefwindow id=d41667e1412 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3964491">Free Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d41667e1421 class=n-a></a>Rigby MR, DiMeglio LA, Rendell MS, <i> et al.</i>: Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. <i>Lancet Diabetes Endocrinol.</i> 2013; <b>1</b>(4): 284–94. <a target=xrefwindow id=d41667e1432 href="http://www.ncbi.nlm.nih.gov/pubmed/24622414">PubMed Abstract </a> | <a target=xrefwindow id=d41667e1435 href="https://doi.org/10.1016/S2213-8587(13)70111-6">Publisher Full Text </a> | <a target=xrefwindow id=d41667e1439 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3957186">Free Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d41667e1448 class=n-a></a>Rigby MR, Harris KM, Pinckney A, <i> et al.</i>: Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. <i>J Clin Invest.</i> 2015; <b>125</b>(8): 3285–96. <a target=xrefwindow id=d41667e1459 href="http://www.ncbi.nlm.nih.gov/pubmed/26193635">PubMed Abstract </a> | <a target=xrefwindow id=d41667e1462 href="https://doi.org/10.1172/JCI81722">Publisher Full Text </a> | <a target=xrefwindow id=d41667e1466 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4623571">Free Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d41667e1475 class=n-a></a>Haller MJ, Schatz DA, Skyler JS, <i> et al.</i>: Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β-Cell Function and Improves HbA<i>1c</i> in New-Onset Type 1 Diabetes. <i>Diabetes Care.</i> 2018; <b>41</b>(9): 1917–25. <a target=xrefwindow id=d41667e1489 href="http://www.ncbi.nlm.nih.gov/pubmed/30012675">PubMed Abstract </a> | <a target=xrefwindow id=d41667e1493 href="https://doi.org/10.2337/dc18-0494">Publisher Full Text </a> | <a target=xrefwindow id=d41667e1496 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6105329">Free Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d41667e1506 class=n-a></a>Haller MJ, Long SA, Blanchfield JL, <i> et al.</i>: Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA<sub>1c</sub>, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data. <i>Diabetes.</i> 2019; <b>68</b>(6): 1267–76. <a target=xrefwindow id=d41667e1520 href="http://www.ncbi.nlm.nih.gov/pubmed/30967424">PubMed Abstract </a> | <a target=xrefwindow id=d41667e1524 href="https://doi.org/10.2337/db19-0057">Publisher Full Text </a> | <a target=xrefwindow id=d41667e1527 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6610026">Free Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/1279979"><span class="faculty-opinion-icon small"></span></a><a name=d41667e1536 class=n-a></a>Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, <i> et al.</i>: Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. <i>N Engl J Med.</i> 2009; <b>361</b>(22): 2143–52. <a target=xrefwindow id=d41667e1547 href="http://www.ncbi.nlm.nih.gov/pubmed/19940299">PubMed Abstract </a> | <a target=xrefwindow id=d41667e1550 href="https://doi.org/10.1056/NEJMoa0904452">Publisher Full Text </a> | <a target=xrefwindow id=d41667e1554 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6410357">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/1279979">Faculty Opinions Recommendation</a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d41667e1567 class=n-a></a>Pescovitz MD, Greenbaum CJ, Bundy B, <i> et al.</i>: B-lymphocyte depletion with rituximab and β-cell function: Two-year results. <i>Diabetes Care.</i> 2014; <b>37</b>(2): 453–9. <a target=xrefwindow id=d41667e1578 href="http://www.ncbi.nlm.nih.gov/pubmed/24026563">PubMed Abstract </a> | <a target=xrefwindow id=d41667e1581 href="https://doi.org/10.2337/dc13-0626">Publisher Full Text </a> | <a target=xrefwindow id=d41667e1585 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3898764">Free Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d41667e1594 class=n-a></a>Herold KC, Gitelman SE, Willi SM, <i> et al.</i>: Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: A randomised controlled trial. <i>Diabetologia.</i> 2013; <b>56</b>(2): 391–400. <a target=xrefwindow id=d41667e1605 href="http://www.ncbi.nlm.nih.gov/pubmed/23086558">PubMed Abstract </a> | <a target=xrefwindow id=d41667e1608 href="https://doi.org/10.1007/s00125-012-2753-4">Publisher Full Text </a> | <a target=xrefwindow id=d41667e1612 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3537871">Free Full Text </a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/1008531"><span class="faculty-opinion-icon small"></span></a><a name=d41667e1621 class=n-a></a>Herold KC, Hagopian W, Auger JA, <i> et al.</i>: Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. <i>N Engl J Med.</i> 2002; <b>346</b>(22): 1692–8. <a target=xrefwindow id=d41667e1632 href="http://www.ncbi.nlm.nih.gov/pubmed/12037148">PubMed Abstract </a> | <a target=xrefwindow id=d41667e1635 href="https://doi.org/10.1056/NEJMoa012864">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/1008531">Faculty Opinions Recommendation</a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d41667e1648 class=n-a></a>Herold KC, Gitelman SE, Ehlers MR, <i> et al.</i>: Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: Metabolic and immunologic features at baseline identify a subgroup of responders. <i>Diabetes.</i> 2013; <b>62</b>(11): 3766–74. <a target=xrefwindow id=d41667e1659 href="http://www.ncbi.nlm.nih.gov/pubmed/23835333">PubMed Abstract </a> | <a target=xrefwindow id=d41667e1662 href="https://doi.org/10.2337/db13-0345">Publisher Full Text </a> | <a target=xrefwindow id=d41667e1666 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3806618">Free Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/728731488"><span class="faculty-opinion-icon small"></span></a><a name=d41667e1676 class=n-a></a>Ziegler AG, Danne T, Dunger DB, <i> et al.</i>: Primary prevention of beta-cell autoimmunity and type 1 diabetes - The Global Platform for the Prevention of Autoimmune Diabetes (GPPAD) perspectives. <i>Mol Metab.</i> 2016; <b>5</b>(4): 255–62. <a target=xrefwindow id=d41667e1687 href="http://www.ncbi.nlm.nih.gov/pubmed/27069865">PubMed Abstract </a> | <a target=xrefwindow id=d41667e1690 href="https://doi.org/10.1016/j.molmet.2016.02.003">Publisher Full Text </a> | <a target=xrefwindow id=d41667e1694 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4811998">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/728731488">Faculty Opinions Recommendation</a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d41667e1707 class=n-a></a>Clinicaltrials.gov: Hydroxychloroquine in Individuals At-risk for Type 1 Diabetes Mellitus. Last updated Feb 12, 2018. Accessed March 20, 2018. <a target=xrefwindow id=d41667e1709 href="https://clinicaltrials.gov/ct2/show/NCT03428945">Reference Source</a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d41667e1718 class=n-a></a>Writing Committee for the Type 1 Diabetes TrialNet Oral Insulin Study Group;Krischer JP, Lynch KF, Schatz DA, <i> et al.</i>: The 6 year incidence of diabetes-associated autoantibodies in genetically at-risk children: The TEDDY study. <i>Diabetologia.</i> 2015; <b>58</b>(5): 980–7. <a target=xrefwindow id=d41667e1729 href="http://www.ncbi.nlm.nih.gov/pubmed/25660258">PubMed Abstract </a> | <a target=xrefwindow id=d41667e1732 href="https://doi.org/10.1007/s00125-015-3514-y">Publisher Full Text </a> | <a target=xrefwindow id=d41667e1736 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4393776">Free Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d41667e1745 class=n-a></a>Ziegler AG, Standl E, Albert E, <i> et al.</i>: HLA-associated insulin autoantibody formation in newly diagnosed type I diabetic patients. <i>Diabetes.</i> 1991; <b>40</b>(9): 1146–9. <a target=xrefwindow id=d41667e1756 href="http://www.ncbi.nlm.nih.gov/pubmed/1936622">PubMed Abstract </a> | <a target=xrefwindow id=d41667e1759 href="https://doi.org/10.2337/diab.40.9.1146">Publisher Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/732655962"><span class="faculty-opinion-icon small"></span></a><a name=d41667e1768 class=n-a></a>Ostrov DA, Alkanani A, McDaniel KA, <i> et al.</i>: Methyldopa blocks MHC class II binding to disease-specific antigens in autoimmune diabetes. <i>J Clin Invest.</i> 2018; <b>128</b>(5): 1888–902. <a target=xrefwindow id=d41667e1779 href="http://www.ncbi.nlm.nih.gov/pubmed/29438107">PubMed Abstract </a> | <a target=xrefwindow id=d41667e1782 href="https://doi.org/10.1172/JCI97739">Publisher Full Text </a> | <a target=xrefwindow id=d41667e1786 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5919818">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/732655962">Faculty Opinions Recommendation</a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d41667e1799 class=n-a></a>Clinicaltrials.gov: Methyldopa for Reduction of DQ8 Antigen Presentation in At-Risk Subjects for Type 1 Diabetes. Last updated March 2, 2018. Accessed March 20, 2018. <a target=xrefwindow id=d41667e1801 href="https://clinicaltrials.gov/ct2/show/NCT03396484">Reference Source</a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/730591836"><span class="faculty-opinion-icon small"></span></a><a name=d41667e1811 class=n-a></a>Long SA, Thorpe J, Herold KC, <i> et al.</i>: Remodeling T cell compartments during anti-CD3 immunotherapy of type 1 diabetes. <i>Cell Immunol.</i> 2017; <b>319</b>: 3–9. <a target=xrefwindow id=d41667e1822 href="http://www.ncbi.nlm.nih.gov/pubmed/28844471">PubMed Abstract </a> | <a target=xrefwindow id=d41667e1825 href="https://doi.org/10.1016/j.cellimm.2017.07.007">Publisher Full Text </a> | <a target=xrefwindow id=d41667e1829 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5614459">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/730591836">Faculty Opinions Recommendation</a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d41667e1842 class=n-a></a>Wherrett DK, Chiang JL, Delamater AM, <i> et al.</i>: Defining Pathways for Development of Disease-Modifying Therapies in Children With Type 1 Diabetes: A Consensus Report. <i>Diabetes Care.</i> 2015; <b>38</b>(10): 1975–85. <a target=xrefwindow id=d41667e1853 href="http://www.ncbi.nlm.nih.gov/pubmed/26404927">PubMed Abstract </a> | <a target=xrefwindow id=d41667e1856 href="https://doi.org/10.2337/dc15-1429">Publisher Full Text </a> | <a target=xrefwindow id=d41667e1860 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4876737">Free Full Text </a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/718400664"><span class="faculty-opinion-icon small"></span></a><a name=d41667e1869 class=n-a></a>Greenbaum CJ, Beam CA, Boulware D, <i> et al.</i>: Fall in C-Peptide During First 2 Years From Diagnosis: Evidence of at Least Two Distinct Phases From Composite Type 1 Diabetes TrialNet Data. <i>Diabetes.</i> 2012; <b>61</b>(8): 2066–73. <a target=xrefwindow id=d41667e1880 href="http://www.ncbi.nlm.nih.gov/pubmed/22688329">PubMed Abstract </a> | <a target=xrefwindow id=d41667e1883 href="https://doi.org/10.2337/db11-1538">Publisher Full Text </a> | <a target=xrefwindow id=d41667e1887 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3402330">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/718400664">Faculty Opinions Recommendation</a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d41667e1900 class=n-a></a>Davis AK, DuBose SN, Haller MJ, <i> et al.</i>: Prevalence of detectable C-Peptide according to age at diagnosis and duration of type 1 diabetes. <i>Diabetes Care.</i> 2015; <b>38</b>(3): 476–81. <a target=xrefwindow id=d41667e1911 href="http://www.ncbi.nlm.nih.gov/pubmed/25519448">PubMed Abstract </a> | <a target=xrefwindow id=d41667e1914 href="https://doi.org/10.2337/dc14-1952">Publisher Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/726132382"><span class="faculty-opinion-icon small"></span></a><a name=d41667e1923 class=n-a></a>Leete P, Willcox A, Krogvold L, <i> et al.</i>: Differential Insulitic Profiles Determine the Extent of β-Cell Destruction and the Age at Onset of Type 1 Diabetes. <i>Diabetes.</i> 2016; <b>65</b>(5): 1362–9. <a target=xrefwindow id=d41667e1934 href="http://www.ncbi.nlm.nih.gov/pubmed/26858360">PubMed Abstract </a> | <a target=xrefwindow id=d41667e1937 href="https://doi.org/10.2337/db15-1615">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/726132382">Faculty Opinions Recommendation</a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d41667e1950 class=n-a></a>Dufort MJ, Greenbaum CJ, Speake C, <i> et al.</i>: Cell type–specific immune phenotypes predict loss of insulin secretion in new-onset type 1 diabetes. <i>JCI Insight.</i> 2019; <b>4</b>(4): e125556. <a target=xrefwindow id=d41667e1961 href="http://www.ncbi.nlm.nih.gov/pubmed/30830868">PubMed Abstract </a> | <a target=xrefwindow id=d41667e1964 href="https://doi.org/10.1172/jci.insight.125556">Publisher Full Text </a> | <a target=xrefwindow id=d41667e1968 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6478408">Free Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d41667e1978 class=n-a></a>Knip M, Kukko M, Kulmala P, <i> et al.</i>: Humoral beta-cell autoimmunity in relation to HLA-defined disease susceptibility in preclinical and clinical type 1 diabetes. <i>Am J Med Genet.</i> 2002; <b>115</b>(1): 48–54. <a target=xrefwindow id=d41667e1989 href="http://www.ncbi.nlm.nih.gov/pubmed/12116176">PubMed Abstract </a> | <a target=xrefwindow id=d41667e1992 href="https://doi.org/10.1002/ajmg.10343">Publisher Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d41667e2001 class=n-a></a>Steck AK, Vehik K, Bonifacio E, <i> et al.</i>: Predictors of Progression From the Appearance of Islet Autoantibodies to Early Childhood Diabetes: The Environmental Determinants of Diabetes in the Young (TEDDY). <i>Diabetes Care.</i> 2015; <b>38</b>(5): 808–13. <a target=xrefwindow id=d41667e2012 href="http://www.ncbi.nlm.nih.gov/pubmed/25665818">PubMed Abstract </a> | <a target=xrefwindow id=d41667e2015 href="https://doi.org/10.2337/dc14-2426">Publisher Full Text </a> | <a target=xrefwindow id=d41667e2019 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4407751">Free Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d41667e2028 class=n-a></a>Redondo MJ, Babu S, Zeidler A, <i> et al.</i>: Specific human leukocyte antigen DQ influence on expression of antiislet autoantibodies and progression to type 1 diabetes. <i>J Clin Endocrinol Metab.</i> 2006; <b>91</b>(5): 1705–13. <a target=xrefwindow id=d41667e2039 href="http://www.ncbi.nlm.nih.gov/pubmed/16464953">PubMed Abstract </a> | <a target=xrefwindow id=d41667e2042 href="https://doi.org/10.1210/jc.2005-1695">Publisher Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d41667e2051 class=n-a></a>Achenbach P, Hummel M, Thümer L, <i> et al.</i>: Characteristics of rapid vs slow progression to type 1 diabetes in multiple islet autoantibody-positive children. <i>Diabetologia.</i> 2013; <b>56</b>(7): 1615–22. <a target=xrefwindow id=d41667e2062 href="http://www.ncbi.nlm.nih.gov/pubmed/23539116">PubMed Abstract </a> | <a target=xrefwindow id=d41667e2065 href="https://doi.org/10.1007/s00125-013-2896-y">Publisher Full Text </a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/732784116"><span class="faculty-opinion-icon small"></span></a><a name=d41667e2074 class=n-a></a>Pallmann P, Bedding AW, Choodari-Oskooei B, <i> et al.</i>: Adaptive designs in clinical trials: Why use them, and how to run and report them. <i>BMC Med.</i> 2018; <b>16</b>(1): 29. <a target=xrefwindow id=d41667e2085 href="http://www.ncbi.nlm.nih.gov/pubmed/29490655">PubMed Abstract </a> | <a target=xrefwindow id=d41667e2088 href="https://doi.org/10.1186/s12916-018-1017-7">Publisher Full Text </a> | <a target=xrefwindow id=d41667e2092 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5830330">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/732784116">Faculty Opinions Recommendation</a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/733896751"><span class="faculty-opinion-icon small"></span></a><a name=d41667e2105 class=n-a></a>Wentworth JM, Bediaga NG, Giles LC, <i> et al.</i>: Beta cell function in type 1 diabetes determined from clinical and fasting biochemical variables. <i>Diabetologia.</i> 2019; <b>62</b>(1): 33–40. <a target=xrefwindow id=d41667e2116 href="http://www.ncbi.nlm.nih.gov/pubmed/30167735">PubMed Abstract </a> | <a target=xrefwindow id=d41667e2119 href="https://doi.org/10.1007/s00125-018-4722-z ">Publisher Full Text </a> | <a target=xrefwindow id=d41667e2123 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6518395">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/733896751">Faculty Opinions Recommendation</a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/727763038"><span class="faculty-opinion-icon small"></span></a><a name=d41667e2137 class=n-a></a>Johnson SB, Lynch KF, Roth R, <i> et al.</i>: My Child Is Islet Autoantibody Positive: Impact on Parental Anxiety. <i>Diabetes Care.</i> 2017; <b>40</b>(9): 1167–72. <a target=xrefwindow id=d41667e2148 href="http://www.ncbi.nlm.nih.gov/pubmed/28663383">PubMed Abstract </a> | <a target=xrefwindow id=d41667e2151 href="https://doi.org/10.2337/dc17-0166">Publisher Full Text </a> | <a target=xrefwindow id=d41667e2155 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5566282">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/727763038">Faculty Opinions Recommendation</a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/732911480"><span class="faculty-opinion-icon small"></span></a><a name=d41667e2168 class=n-a></a>Smith LB, Liu X, Johnson SB, <i> et al.</i>: Family adjustment to diabetes diagnosis in children: Can participation in a study on type 1 diabetes genetic risk be helpful? <i>Pediatr Diabetes.</i> 2018; <b>19</b>(5): 1025–33. <a target=xrefwindow id=d41667e2179 href="http://www.ncbi.nlm.nih.gov/pubmed/29577538">PubMed Abstract </a> | <a target=xrefwindow id=d41667e2182 href="https://doi.org/10.1111/pedi.12674">Publisher Full Text </a> | <a target=xrefwindow id=d41667e2186 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6030424">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/732911480">Faculty Opinions Recommendation</a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d41667e2199 class=n-a></a>Warncke K, Krasmann M, Puff R, <i> et al.</i>: Does diabetes appear in distinct phenotypes in young people? Results of the diabetes mellitus incidence Cohort Registry (DiMelli). <i>PLoS One.</i> 2013; <b>8</b>(9): e74339. <a target=xrefwindow id=d41667e2210 href="http://www.ncbi.nlm.nih.gov/pubmed/24023937">PubMed Abstract </a> | <a target=xrefwindow id=d41667e2213 href="https://doi.org/ 10.1371/journal.pone.0074339">Publisher Full Text </a> | <a target=xrefwindow id=d41667e2217 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3762796">Free Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/736640402"><span class="faculty-opinion-icon small"></span></a><a name=d41667e2226 class=n-a></a>Dayan CM, Korah M, Tatovic D, <i> et al.</i>: Changing the landscape for type 1 diabetes: The first step to prevention. <i>Lancet.</i> 2019; <b>394</b>(10205): 1286–96. <a target=xrefwindow id=d41667e2237 href="http://www.ncbi.nlm.nih.gov/pubmed/31533907">PubMed Abstract </a> | <a target=xrefwindow id=d41667e2240 href="https://doi.org/10.1016/S0140-6736(19)32127-0">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/736640402">Faculty Opinions Recommendation</a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/1124054"><span class="faculty-opinion-icon small"></span></a><a name=d41667e2253 class=n-a></a>Emery P, Breedveld FC, Hall S, <i> et al.</i>: Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): A randomised, double-blind, parallel treatment trial. <i>Lancet.</i> 2008; <b>372</b>(9636): 375–82. <a target=xrefwindow id=d41667e2264 href="http://www.ncbi.nlm.nih.gov/pubmed/18635256">PubMed Abstract </a> | <a target=xrefwindow id=d41667e2267 href="https://doi.org/10.1016/S0140-6736(08)61000-4">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/1124054">Faculty Opinions Recommendation</a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/2953958"><span class="faculty-opinion-icon small"></span></a><a name=d41667e2280 class=n-a></a>Colombel JF, Sandborn WJ, Reinisch W, <i> et al.</i>: Infliximab, azathioprine, or combination therapy for Crohn's disease. <i>N Engl J Med.</i> 2010; <b>362</b>(15): 1383–95. <a target=xrefwindow id=d41667e2291 href="http://www.ncbi.nlm.nih.gov/pubmed/20393175">PubMed Abstract </a> | <a target=xrefwindow id=d41667e2294 href="https://doi.org/10.1056/NEJMoa0904492">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/2953958">Faculty Opinions Recommendation</a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d41667e2308 class=n-a></a>Linsley PS, Greenbaum CJ, Speake C, <i> et al.</i>: B lymphocyte alterations accompany abatacept resistance in new-onset type 1 diabetes. <i>JCI Insight.</i> 2019; <b>4</b>(4): e126136. <a target=xrefwindow id=d41667e2319 href="http://www.ncbi.nlm.nih.gov/pubmed/30830871">PubMed Abstract </a> | <a target=xrefwindow id=d41667e2322 href="https://doi.org/ 10.1172/jci.insight.126136">Publisher Full Text </a> | <a target=xrefwindow id=d41667e2326 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6478438">Free Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d41667e2335 class=n-a></a>Linsley PS, Greenbaum CJ, Rosasco M, <i> et al.</i>: Elevated T cell levels in peripheral blood predict poor clinical response following rituximab treatment in new-onset type 1 diabetes. <i>Genes Immun.</i> 2019; <b>20</b>(4): 293–307. <a target=xrefwindow id=d41667e2346 href="http://www.ncbi.nlm.nih.gov/pubmed/29925930">PubMed Abstract </a> | <a target=xrefwindow id=d41667e2349 href="https://doi.org/10.1038/s41435-018-0032-1">Publisher Full Text </a> | <a target=xrefwindow id=d41667e2353 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6477779">Free Full Text </a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 30 Jul 2020</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/9-827/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/9-827/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Benaroya Research Institute at Virginia Mason, Seattle, WA, 98101, USA<br/> <p> <div class=margin-bottom> Sandra Lord <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation </div> <div class=margin-bottom> Carla J. Greenbaum <br/> <span>Roles: </span> Conceptualization, Supervision, Writing – Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/9-827/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 30 Jul 2020, 9:827 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.21801.1">https://doi.org/10.12688/f1000research.21801.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2020 Lord S and Greenbaum CJ. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=24032 data-id=21801 data-downloads="" data-views="" data-scholar="10.12688/f1000research.21801.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/9-827/v1/pdf?article_uuid=3e5482a1-c3d1-4f0e-ab14-b9277814a65c" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.21801.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Lord S and Greenbaum CJ. Insulin is necessary but not sufficient: changing the therapeutic paradigm in type 1 diabetes [version 1; peer review: 5 approved] <i>F1000Research</i> 2020, <b>9</b>(Faculty Rev):827 (<a href="https://doi.org/10.12688/f1000research.21801.1" target=_blank>https://doi.org/10.12688/f1000research.21801.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=21801 id=mobile-track-article-signin-21801 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/21801?target=/articles/9-827/v1"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=24032 /> <input name=articleId type=hidden value=21801 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Chantal Mathieu</strong>, Department of Endocrinology, UZ Gasthuisberg, KU Leuven, Belgium </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Ezio Bonifacio</strong>, Centre for Regenerative Therapies Dresden (CRTD), Faculty of Medicine, Technische Universität Dresden, Germany </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Colin M. Dayan</strong>, Diabetes Research Group, Cardiff University School of Medicine, UK </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Stephan Kissler</strong>, Section for Immunobiology, Joslin Diabetes Center, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Todd Brusko</strong>, Department of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida Diabetes Institute, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> Todd M. Brusko has collaborated with the authors on two consortium papers in the last three years (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 30 Jul 2020</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/9-827/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/9-827/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=73268-68409></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=73272-68407></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=73271-68406></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=73269-68410></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=73270-68405></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=5><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> <th class="c-report-timeline__headings-version p-article__color--dark">3</th> <th class="c-report-timeline__headings-version p-article__color--dark">4</th> <th class="c-report-timeline__headings-version p-article__color--dark">5</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/9-827/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>30 Jul 20</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Chantal Mathieu</strong>, Department of Endocrinology, UZ Gasthuisberg, KU Leuven, Belgium </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Ezio Bonifacio</strong>, Centre for Regenerative Therapies Dresden (CRTD), Faculty of Medicine, Technische Universität Dresden, Germany </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Colin M. Dayan</strong>, Diabetes Research Group, Cardiff University School of Medicine, UK </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Stephan Kissler</strong>, Section for Immunobiology, Joslin Diabetes Center, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Todd Brusko</strong>, Department of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida Diabetes Institute, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> Todd M. Brusko has collaborated with the authors on two consortium papers in the last three years </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/9-827/v1&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/9-827/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Insulin is necessary but not sufficient:...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/9-827/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/9-827/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/9-827/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Lord S and Greenbaum CJ');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/9-827/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/9-827",
            templates : {
                twitter : "Insulin is necessary but not sufficient: changing the therapeutic.... Lord S and Greenbaum CJ, published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/9-827/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Insulin is necessary but not sufficient: changing the therapeutic paradigm in type 1 diabetes", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Insulin is necessary but not sufficient: changing the therapeutic paradigm in type 1 diabetes", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/21801/24032")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "24032");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "68405": 0,
                           "68407": 1,
                           "68406": 0,
                           "68409": 0,
                           "68408": 0,
                           "68410": 3,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "335d2160-36b3-48ab-a5f2-4c2e2a8a98e6";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-827.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-827.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-827.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/9-827.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/9-827.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>